No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
TWST240719P37500
- 0.30
- -0.10-25.00%
15min DelayClose Jul 5 15:58 ET
0.30High0.30Low
0.30Open0.40Pre Close2 Volume65 Open Interest37.50Strike Price60.00Turnover99.42%IV23.25%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier13DDays to Expiry0.30Extrinsic Value100Contract SizeAmericanOptions Type-0.0731Delta0.0150Gamma149.14Leverage Ratio-0.0466Theta-0.0013Rho-10.90Eff Leverage0.0129Vega
Intraday
- 5D
- Daily
News
We're Not Worried About Twist Bioscience's (NASDAQ:TWST) Cash Burn
Just because a business does not make any money, does not mean that the stock will go down. For example, Twist Bioscience (NASDAQ:TWST) shareholders have done very well over the last year, with the
Cathie Wood's Ark Invest Sells Tesla Shares Worth $14.5M Amid Rally Driven By Q2 Delivery Numbers, Picks Up Palantir Shares Again Today
On Tuesday, Cathie Wood-led Ark Invest made significant adjustments to its portfolio, offloading a substantial number of shares in Tesla Inc (NASDAQ:TSLA) and scooping up a hefty stake in Palantir Tec
Is Twist Bioscience Corporation (TWST) a Good Stock to Buy and Hold for 5 Years?
Form 144 | Twist Bioscience(TWST.US) Officer Proposes to Sell 906.74K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Twist Bioscience(TWST.US)$ Officer Banyai William intends to sell 18,777 shares of its common stock on Jul 1, with a total market value of approximately $906.74K. Ban
Twist Bioscience Is Maintained at Overweight by Barclays
Twist Bioscience Is Maintained at Overweight by Barclays
Express News | Twist Bioscience : Barclays Raises Target Price to $60 From $45
Comments
How does the biotech ecosystem support advancements in personalized medicine & genomics? ![]()
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
7
Twist Bioscience's P/S ratio remains lower due to sub-par revenue outlook, indicating investor expectation of limited future growth. Shareholder pessimism around future revenue growth contributes to this lower ratio.
Twist Bioscience's optimistic cash runway and manageable burn rate are noteworthy despite the need for vigilance as the firm grows. Its market cap also points to easy fundraising potential.
Despite Twist Bioscience's unprofitability, rapid revenue growth indicates positive prospects. However, persistent share price decline hints at capital raising issues. Investors should assess the firm's balance sheet, market conditions and specific risks.
$Twist Bioscience(TWST.US$ Twist Bioscience Announced An Antibody Discovery, Option And License Agreement With Bayer Of Up To $188M. Bayer Will Have The Option To License Antibodies Discovered Under The Collaboration
Read more